Risk factors

New risks emphasize AI deployment, payment-stablecoin competition, operational resilience, and regulatory scrutiny.

The company added a delisting risk regarding NYSE American compliance.

Cloud infrastructure, artificial intelligence, and related data, security, compliance, and liability risks are newly disclosed.

CEVA highlights heightened competition from Arm, Cadence, and open-source RISC-V architectures in NPU and wireless IP. New US tariff uncertainty and shifting Israeli R&D grants threaten financial results. Customer concentration remains high, with UNISOC accounting for 15% of revenues.

New EU and UK rules add compliance, fraud-prevention, securitization, and market-integration risks for Carlyle and its funds.

Clinical execution and first-time BLA submission are newly emphasized as CG Oncology advances cretostimogene through multiple Phase 3 trials.

Chemed added risks regarding severe tariff impacts on Roto-Rooter and VITAS supply chains and vehicle costs. Cyberattack disclosures were expanded following a breach of protected health information. Competition and labor retention risks remain central to the business.

Chatham Lodging Trust added risks concerning artificial intelligence adoption, federal government shutdowns affecting travel, and debt covenants constraining distributions.

Dividend suspension is now a direct investor risk; resumption is uncertain.

Calumet added risks regarding financial restatements, CFPC secondary market reliance, and rail transportation hazards.

Clover Health expanded its risk disclosures regarding membership growth management, HIPAA compliance responsibilities, and financial control obligations. Net losses increased to $85.5 million in 2025, pushing the accumulated deficit to $2.3 billion. Share option and RSU counts were updated for 2025 alongside insider ownership figures.

Capital expenditures are projected to reach $1 billion in 2026 to support hyperscaler demand.